Inari Medical Inc. (Nasdaq: NARI) shares fell 19% after releasing second quarter results.
The Irvine-based maker of devices to remove blood clots reported revenue of $146 million, up 23% from the same quarter last year.
“Our second quarter performance was driven by strong adoption of our market leading solutions across our VTE, Emerging Therapies and international businesses,” Chief Executive Drew Hykes said in a statement.
Shares dropped to $44.05 in after-hours trading. The company’s second-quarter loss was 54 cents when analysts expected a 15-cent loss.
The company today also announced that Chief Financial Officer Mitch Hill will retire, effective October 1.
Hill spent five years in the role and will be succeeded by Kevin Strange, Inari’s current senior vice president of finance, accounting, strategy and business development.
